Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial

Li-Xin Pan, Yi-Yang Wang, Zhong-Hai Li, Jia-Xi Luo, Kun-Jun Wu, Zhen-Xiu Liu, Pei-Sheng Wu, Kang Chen, Liang Ma, Xiao-Hui Fan, Jian-Hong Zhong, Li-Xin Pan, Yi-Yang Wang, Zhong-Hai Li, Jia-Xi Luo, Kun-Jun Wu, Zhen-Xiu Liu, Pei-Sheng Wu, Kang Chen, Liang Ma, Xiao-Hui Fan, Jian-Hong Zhong

Abstract

Background: Entecavir and tenofovir disoproxil fumarate (TDF) are standard first-line treatments to prevent viral reactivation and hepatocellular carcinoma (HCC) in individuals chronically infected with the hepatitis B virus (HBV), but the long-term efficacy of the two drugs remains controversial. Also unclear is whether the drugs are effective at preventing viral reactivation or HCC recurrence after hepatectomy to treat HBV-associated HCC. This trial will compare recurrence-free survival, overall survival, viral indicators and adverse events in the long term between patients with HBV-associated HCC who receive entecavir or TDF after curative resection.

Methods: This study is a randomized, open-label trial. A total of 240 participants will be randomized 1:1 into groups receiving TDF or entecavir monotherapy. The two groups will be compared in terms of recurrence-free and overall survival at 1, 3, and 5 years after surgery; adverse events; virological response; rate of alanine transaminase normalization; and seroreactivity at 24 and 48 weeks after surgery.

Discussion: This study will compare long-term survival between patients with HBV-associated HCC who receive TDF or entecavir monotherapy. Numerous outcomes related to prognosis will be analyzed and compared in this study.

Trial registration: ClinicalTrials.gov NCT02650271. Registered on January 7, 2016.

Keywords: Entecavir; Hepatitis B virus; Hepatocellular carcinoma; Tenofovir disoproxil fumarate.

Conflict of interest statement

No sponsors were involved in this study. The authors declare no conflicts of interest relevant to the content of this article.

© 2024. The Author(s).

Figures

Fig. 1
Fig. 1
Participant flowchart. HBV, hepatitis B virus; HCC, hepatocellular carcinoma

References

    1. Polaris Observatory Collaborators Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403. doi: 10.1016/S2468-1253(18)30056-6.
    1. Cornberg M, Lok AS, Terrault NA, Zoulim F. Faculty E-AHTEC: Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J Hepatol. 2020;72(3):539–557. doi: 10.1016/j.jhep.2019.11.003.
    1. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. American Association for the Study of Liver D: AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283. doi: 10.1002/hep.28156.
    1. de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, Gadano A, Lee Y, Mazzotta F, Thomas N, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology. 2001;34(3):578–582. doi: 10.1053/jhep.2001.26815.
    1. Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al; GSUS-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672–81. 10.1016/j.jhep.2017.11.039.
    1. Lee J, Cho S, Kim HJ, Lee H, Ko MJ, Lim YS. High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: A nationwide cohort study. J Viral Hepat. 2021;28(2):353–363. doi: 10.1111/jvh.13418.
    1. Kuang XJ, Jia RR, Huo RR, Yu JJ, Wang JJ, Xiang BD, Li LQ, Peng Z, Zhong JH. Systematic review of risk factors of hepatocellular carcinoma after Hepatitis B Surface Antigen seroclearance. J Viral Hepat. 2018;25(9):1026–1037. doi: 10.1111/jvh.12905.
    1. Hu TH, Yueh-Hsia Chiu S, Tseng PL, Chen CH, Lu SN, Wang JH, Hung CH, Kee KM, Lin MT, Chang KC, et al. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naive patients with chronic hepatitis B-related compensated cirrhosis in Taiwan. Aliment Pharmacol Ther. 2020;52(11–12):1695–1706. doi: 10.1111/apt.16116.
    1. Cheuk-Fung Yip T, Wai-Sun Wong V, Lik-Yuen Chan H, Tse YK, Chung-Yan Lui G, Lai-Hung Wong G. Tenofovir is associated with lower risk of hepatocellular carcinoma than Entecavir in patients with chronic HBV infection in China. Gastroenterology. 2020;158(1):215–225.e216. doi: 10.1053/j.gastro.2019.09.025.
    1. Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of hepatocellular carcinoma in patients treated with Entecavir vs Tenofovir for chronic hepatitis B: a Korean nationwide cohort Study. JAMA Oncol. 2019;5(1):30–36. doi: 10.1001/jamaoncol.2018.4070.
    1. Oh H, Yoon EL, Jun DW, Ahn SB, Lee HY, Jeong JY, Kim HS, Jeong SW, Kim SE, Shim JJ, et al. No difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with Entecavir vs Tenofovir. Clin Gastroenterol Hepatol. 2020;18(12):2793–2802.e2796. doi: 10.1016/j.cgh.2020.02.046.
    1. Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, Nam SW, Bae SH, Choi JY, Yoon SK, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut. 2020;69(7):1301–1308. doi: 10.1136/gutjnl-2019-318947.
    1. Kim WR, Telep LE, Jump B, Lu M, Ramroth H, Flaherty J, Gaggar A, Chokkalingam AP, Gordon SC. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Aliment Pharmacol Ther. 2022;55(7):828–835. doi: 10.1111/apt.16786.
    1. Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol. 2020;73(5):1037–1045. doi: 10.1016/j.jhep.2020.06.011.
    1. Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol. 2023;78(3):534–42. 10.1016/j.jhep.2022.12.007.
    1. Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, Tang ASP, Lim KE, Lim GEH, Tamaki N, et al. Risk of hepatocellular carcinoma with Tenofovir vs Entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis. JAMA Netw Open. 2022;5(6):e2219407. doi: 10.1001/jamanetworkopen.2022.19407.
    1. Yuan BH, Li RH, Huo RR, Li MJ, Papatheodoridis G, Zhong JH. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J Gastroenterol Hepatol. 2022;37(5):782–794. doi: 10.1111/jgh.15783.
    1. Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1039–1052. doi: 10.1016/S2468-1253(20)30249-1.
    1. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890–897. doi: 10.1016/j.jhep.2009.07.009.
    1. Qiu JF, Ye JZ, Feng XZ, Qi YP, Ma L, Yuan WP, Zhong JH, Zhang ZM, Xiang BD, Li LQ. Pre- and post-operative HBsAg levels may predict recurrence and survival after curative resection in patients with HBV-associated hepatocellular carcinoma. J Surg Oncol. 2017;116(2):140–148. doi: 10.1002/jso.24628.
    1. Zhong JH. Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. Tumour Biol. 2014;35(12):12779–12784. doi: 10.1007/s13277-014-2881-1.
    1. Li C, Li ZC, Ma L, Li LQ, Zhong JH, Xiang BD, Gong WF. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2020;14(8):749–756. doi: 10.1080/17474124.2020.1784727.
    1. Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology. 2021;73(2):661–673. doi: 10.1002/hep.31289.
    1. Zhang M, Wang D, Liu H, Li H. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agent Cancer. 2018;13:19. doi: 10.1186/s13027-018-0191-8.
    1. Liu H, Han CL, Tian BW, Ding ZN, Yang YF, Ma YL, Yang CC, Meng GX, Xue JS, Wang DX, et al. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2023;17(6):623–633. doi: 10.1080/17474124.2023.2212161.
    1. Lee JH, Kim BK, Park SY, Tak WY, Park JY, Kim DY, Ahn SH, Sinn DH, Kim SU. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. Eur J Intern Med. 2021;89:48–55. doi: 10.1016/j.ejim.2021.02.019.
    1. Kao WY, Tan EC, Lee HL, Huang YH, Huo TI, Chang CC, Chiou JF, Hou MC, Wu JC, Su CW. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. Aliment Pharmacol Ther. 2023;57(11):1299–1312. doi: 10.1111/apt.17438.
    1. Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition) Liver Cancer. 2020;9(6):682–720. doi: 10.1159/000509424.
    1. Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res. 2010;40(10):943–953. doi: 10.1111/j.1872-034X.2010.00710.x.
    1. Zhong JH, Xing BC, Zhang WG, Chan AW, Chong CCN, Serenari M, Peng N, Huang T, Lu SD, Liang ZY, et al. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: retrospective multicentre study. Br J Surg. 2022;109(1):71–78. doi: 10.1093/bjs/znab340.
    1. Chen K, Wei W, Liu L, Deng ZJ, Li L, Liang XM, Guo PP, Qi LN, Zhang ZM, Gong WF, et al. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. Cancer Immunol Immunother. 2022;71(5):1063–1074. doi: 10.1007/s00262-021-03060-w.
    1. Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. [].
    1. Linye H, Zijing X, Xiaoyun Z, Zhihui L, Tianfu W, Chuan L. Tenofovir vs entecavir on the prognosis of hepatitis B-Related hepatocellular carcinoma after surgical resection: a randomised controlled trial. Int J Surg. 2023;109(10):3032–3041. doi: 10.1097/JS9.0000000000000554.
    1. A fifth amendment for the Declaration of Helsinki. Lancet. 2000;356(9236):1123.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera